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Summary.-The hypoxic cell-radiosensitizing drug misonidazole (1-(2-nitro-
imidazol-1-yl)-3-methoxypropan -2 -ol, Ro 07-0582, MIS) was administered at a
dose of 150 mg/kg i.v. to 6 dogs bearing spontaneous tumours, and the resulting
tumour concentrations were measured by HPLC analysis. In 4 dogs it was possible
to obtain serial biopsy specimens up to 5 h.
With the exception of a brain tumour, the tumour concentrations ranged between
470 and95%o of the plasma concentration, most of the values falling within the range
50-70%o. Concentrations in the brain tumour were markedly lower.
Barbiturate anaesthesia was necessary for the removal of the serial biopsy speci-
mens, and the effects of sodium pentobarbitone anaesthesia on the pharmacokinetics
of MIS were investigated in 2 dogs. After barbiturate anaesthesia peak plasma con-
centrations were raised and the availability of MIS was increased, although the bio-
logical half-life remained unaltered. The metabolism of MIS to the 0-demethylated
metabolite, Ro 05-9963, was delayed initially. The concentrations of MIS and Ro
05-9963 in cerebrospinal fluid were also recorded in these dogs; MIS concentrations
were found to approach those of the plasma, whereas the metabolite concentrations
were considerably lower (0-58% of the plasma concentration).
THE 2-nitroimidazole, misonidazole (1-
(2-nitroimidazol- I-yl)-3-methoxypropan-
2-ol, Ro 07-0582 MIS) has been shown to
be an active hypoxic cell radiosensitizer
both in vitro (Asquith et al., 1974; Chap-
man et al., 1974) and in vivo (Denekamp
et al., 1974). It is generally accepted as
being one of the most suitable drugs of its
kind currently available for clinical use,
and several trials are in progress to assess
the effectiveness of this agent as an
adjuvant to the radiotherapy of tumours
in man (Dische et al., 1977; Urtasun et al.,
1977; Wiltshire et al., 1978).
Most ofthe experimental work to evalu-
ate this and other radiosensitizing drugs
has been carried out in vitro or in rodents.
There are, however, some differences
between the behaviour of MIS in rodents
and in man, in particular the much shorter
half-life of the drug in the mouse, which
may possibly limit the use of rodents
as models for studies of radiosensitiz-
ation.
From a recent study of MIS in the dog
(White et al., 1979) it was concluded, in
the light of the similar pharmacokinetic
behaviour ofthe drug in the dog and man,
that this may be a useful species to use as
an intermediate model between rodents
and humans. Notably the half-life of the
drug in this species (4.7 h mean) more
closely resembles that found in man
(4-18 h).
To investigate the pharmacokinetics of
MIS in tumour-bearing dogs, and to
examine the feasibility of a clinical trial
using MIS in this species, we have ex-
amined the concentrations of MIS in the
tumour and plasma of 6 dogs with spon-
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taneous tumours. In 4 of these (logs it was
possible to obtain multiple biopsy speci-
mens up to 5 h after the administration of
t,he drug.
Sodium pentobarbitone was used as an
anaesthetic agent for the dogs from which
biopsy specimens were taken, and we have
therefore examined the effects of this drug
on the pharmacokinetics of MIS in 2 dogs
uised in this study. The cerebrospinal fluid
concentrations ofMIS and its 0-demethyl-
ated metabolite, Ro 05-9963, were also
measured in these dogs.
AIATERIALS AND METHODS
Experimniental dogs
The 2 dogs used in this study -were adult
crossbred Collies Aweighing 19 kg and 35 kg.
Both were clinically normal. Their routine
haematological and biochemical values -were
within normal limits, and were subsequently
monitored during the study.
Misonidazole (Roche Products Ltd.) was
prepared for i.v. injection at a concentration
of 50 in 0-9%o NaCl solution. In all cases
misonidazole was administered at a dose of
150 mg/kg.
Week 1. Both dogs received MIS by
injection into the right cephalic vein. This
site was subsequently avoided for blood
sampling.
Dog 1 (19 kg) w%vas then immediately
anaesthetized by the i.v. injection of sodium
pentobarbitone (Sagatal, May and Baker) at a
dose of 30 mg/kg in order to induce medium
Stage 3 general anaesthesia lasting 6 h.
Blood samples were then taken into heparin
at the following times: 10 min, 30 min, 1, 2.
3, 4, 5, 6, 9, 12, 18, 24, 30 and 36 h.
Week 2. Seven days after the first study
MIS was again administered to both dogs.
Dog 2 (35 kg) was then immediately
anaesthetized using the same procedure as for
Dog 1. Blood samples were taken as before.
Week 3-Seven days after the second study
MIS was again administered to both dogs.
Both dogs were then anaesthetized using the
previous procedure.
Blood samples were taken from both dogs
at 1, 2, 3, 4, and 5 h. At the same times
2 ml samples ofcerebrospinal fluid (CSF) were
taken from each dog by cisternal puncture.
All plasma, CSF and tissue samples from
this and subsequent studies were stored at
-20°C before assay for MIS and its 0-
demethylated metabolite, Ro 05-9963.
Samples were assayed by HPLC analysis
using the technique described by Workman
et al. (1978a). The estimation of pharmaco-
kinetic parameters was made using the
methods described previously by White
et al. (1979).
Clinical materiial Group A
Two dogs bearing spontaneous tumours
were presented at the Department of Clinical
Veterinary Medicine for euthanasia. Their
condition wAas judged by 2 clinicians as
being incurable and having reached a ter-
minal stage.
Case 1. An 8-year-old male Pyrennean
Mountain dog weighing 63-5 kg presented
with a, neoplastic enlargement of the right
proximal radius.
Case 2.-A 9-year-old Labrador dog wNeigh-
ing 30 kg presented with a progressive history
of neurological symptoms attributable to a
brain tumour.
MIS was administered to Cases 1 and 2 and
other subsequent clinical patients at a dose of
150 mig/kg by i.v. injection. Euthanasia was
subsequently carried out on both dogs using
i.v. sodium pentobarbitone 20% (Euthatal,
May and Baker). In the case of Dog 1 a
period of 1-5 h elapsed bet-ween drug adminis-
tration and euthanasia, for Dog 2 a period of
3.5 h.
Blood samples wNere collected from each
dog at the time of euthanasia. A CSF sample
wA-as also collected from Dog 2 by cisternal
puncture.
Immediate postmortem examination was
carried out on each dog and representative
areas of tumour were removed for storage
and assay. Adjacent tumour samples were
removed for histological examination.
Postmnortem examination of Dog 1 con-
firmed the presence of a highly destructive
lesion of the proximal radius. Samples of
the lesion wiere taken from necrotic, haemor-
rhagic and apparently normal areas and from
an area ofinuscular attachment.
Postmortem examination of Dog 2 revealed
a right,-sided pedunculated mass involving
the brain in the region of the origin of the
Vth cranial nerve and invading, the surround-
ing petrous temporal bone. Samples of the
mass were taken from the pedicle base and
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from the remainder ofthe pedicle. Samples of
cerebral cortex, thalamus, cerebellum and
brain stem were also obtained.
Clinical material-Group B
Four dogs were presented at the Depart-
ment of Clinical Veterinary Medicine for the
radiation treatment of various spontaneous
tumours.
Case 3.-A 9-year-old Labrador bitch
weighing 27 kg presented with a mammary
tumour surrounded by multiple s.c. meta-
stases.
Case 4.-A 1-year-old mongrel bitch weigh-
ing 10 kg presented with multiple cutaneous
tumours.
Ca-se 5.-A 7-year-old Setter dog, weighing
30 kg, presented with a mandibular sym-
physeal tumour.
Case 6.-A 10-year-old mongrel dog weigh-
ing 19 kg presented with a tonsillar tumour.
Before radiotherapy was performed MIS
was administered i.v. to each dog. The dogs
were then anaesthetized using sodium pento-
barbitone at a dose of30 mg/kg. Bloodsamples
were taken from all dogs at 1, 2, 3, 4 and 5 h.
At the same times small biopsy specimens
(> 10 mg) were taken from the lesions;
samples were also removed for histological
examination.
In the case ofDog 3 samples were removed
from the major mammary mass and from the
satellite nodules at each sampling time.
Samples were taken from separate lesions
at each time in the case ofDog 4.
Serial samples were taken from adjacent
areas of the lesions at each sampling time for
Dogs 5 and 6.
RESULTS
Experimtental data
Misonidazole and sirnultaneous barbiti -
rate anaesthesia. Table I shows various
pharmacokinetic parameters for MIS and
its 0-demethylated metabolite Ro 05-
9963, with and without simultaneous
sodium pentobarbitone-induced anaes-
thesia. The plasma MIS and metabolite
concentrations are plotted against time in
Fig. 1 for Dog 1.
(i) Peak plasma MIS concentrations.
After admninistration of sodium pentobar-
bitonethe peakplasmaMIS concentrations
were raised in both dogs (Table I), by I11%
in Dog 1 and 13% in Dog 2. Although the
peak occurred later in Dog 1 it occurred at
the same time in Dog 2.
(ii) Half-life. After sodium pentobarbi-
tone anaesthesia the half-life (T1/2) for the
elimination phase of the plasma concen-
tration was essentially unaltered in both
dogs.
(iii) Area under the curte (AUC). After
sodium pentobarbitone anaesthesia the
AUC was increased in both dogs, by 23%
in Dog 1 and 35% for Dog 2.
TABLE I.-Pharmnacokinetic data for 2 dogs after 150 mig/kg i.v. tmisonidazole (MIS)
with and without 30 mg/kg i.v. N\a pentobartibone (Barb)
Peak
concen-
tration
Treatment (Kig/ml)
Dog 1 MIS+ Barb. 200
AiIS 180
Dog 2 MIS 197
MIS+Barb. 223
Plasma MIS
Peak T1/2t AUC*
time (h) (tLg/ml. h)
1 h 4-9
(45 5-55)
5 min 6-1
(5.2-7.3)
30 min 5-8
(4.1-9 8)
30 min 6-7
(5-8 7.9)
1942
I1'l
Peak
concen-
tration
(Gtg/ml)
7-8
lasma Ho 05-9963
1'eak AUC*
time (Hg/ml.h)
9 h 171
1583 11 9 30 mill 231
1861 11-( 4h 226
2489) 8-6 20 h 231
* Area under the curve.
t 95% confidence limits for T1/2 in parentheses.
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(iv) O-demnethylated metabolite Ro 05-9963.
The 0-demethylated metabolite of MIS,
Ro 05-9963, wTas detected in the plasma of
both dogs, both with and without anaes-
thesia. Values of the relevant pharmaco-
kinetic variables are presented in Table I
and the plasma concentrations are plotted
against tinme in Fig. I for Dog 1.
It can be seen that the peak plasma
metabolite concentrations were redtuced in
both dogs after sodium pentobarbitone
anaesthesia. The appearance of the peak
plasma metabolite concentratioins was
mnarkedly dlelayeed in both (logs.
AV'alues of the AUC for the metabolite
were approximately 10-15% of the corres-
pon(ling MIS values. AUC values were
generally unchanged by barbiturate anaes-
thesia.
Cerebrospinal fltuid concentrations.
After the administration of MIS to the 2
dogs subsequtently anaesthetized, both
MIS and its 0-demethylated metabolite,
ho 05-9963, were detectecl in the CSF. The
plasma an(1 CSF concentrations of mis-
onidlazole and ho 05-9963 are presented
in Table II anid are plotted against a linear
time scale in Fig. 2 for Dog 1.
Misonidazole. Peak plasma con centra-
tions were recorded at! 2 and I h in Dogs
1 and 2 respectively; thereafter plasma
concentrations fell gradually.
C(SF concentrations in Dog I were
almost as high as those in the plasma,
especially after 2 h (Fig. 2), representing
an overall mean of 88 + 70 (s.d.) of their
corresponding plasma concentrations.
It will be seen that the initial CSF con-
centrations for Dog 2 (at 1 and 2 h) were
comparatively low (46 and 68% of the
plasma concentrations). Subsequent con-
centrations over the period 3-5 h were
much higher. ('onsequently the CSF con-
centrations represented an overall mean
TABLE II. Plasma and cerebrospinal flutid nitroinmidazole concentrations (tyg/ml) after
150 mg/kg i.v. MIS and 30 my/kg i.v. Na pentobarbitone in 2 dogs
MI S S Ro 059963
Time? As o(f As 0° of
(h) I'lasIna CSF plasma Il'asma (SF plasma
1 -)3209 170 81 27 0 4 15
Dog 1 2 214 178 84 4 6 1-8 40
:3 196 191 97 5-7 2-5 44
4 186 174 94 6-6 3-7 58
.5) 172 148 86 6;9 3:3 48
IDog 2 1 221 1(1 46 41 0 0
2 20:3 138 68 5-7 0-6 1 1
3 202 184 91 7-5 2-9 40
4 184 175 95 8-4 3-6 43
5 191 165 86 9-4 :3'3 42_ 11 11R. A. S. WHITE, P. WORKMAN, L. N. OWEN ANI) N. M. BLEEHEN
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FiG. 2. Plasma and: cerebrospinal fluid nitro-
imicdazole concentrations after a (lose of
150 mg/kg i.v. MIS and Na pentobarbitone
anaesthesia. 0 Plasma MIS; 0 CSF MIS;
A Plasma Ro 05-9963; A CSF Ro 05-9963.
of 77 + 200% of their corresponding plasma
concentrations.
The maximum MIS concentrations in
the CSF were recorded at 3 h in both dogs,
whilst the maximum CSF: plasma concen-
tration ratios of 97 and 9500 were
recorded at 3 and 4 h respectively.
Ro 05-9963. Plasma concentrations ofthe
metabolite, Ro 05 9963, were much lower
than corresponding MIS concentrations.
In both dogs the plasma concentrations
rose steadily to peak at 5 h, and the CSF
metabolite concentrations followed a simi-
lar pattern. However, the CSF: plasma
concentration ratios were considerably
lower than for MIS. In Dog 1 the CSF
concentrations ranged between 15 and
5800 of the corresponding plasma concen-
trations and between 0 and 42% in Dog 2.
Maximum metabolite concentrations in
CSF were recorded at 4 and 5 h, whilst the
maximum CSF: plasma metabolite ratios
of 58 and 430 were both recorded at 5 h.
Clinical material
(i) Histopathology. The histopatho-
logical identification of the tumours from
Cases 1-6 are presented in Table III with
comments on individual variation between
biopsy specimens.
(ii) Plasma MIS and metabolite concen-
trations. The plasma and tumour con-
centrations of MIS and Ro 05-9963 in
Cases 1-6 are recorded in Tables IV a-f,
and the tumour concentrations are also
expressed as percentages of the corres-
TABLE III. Histopathological identification of tumours in Cases 1-6
Case Histological type
I Osteosarcoma
2 Aleningionia
3 Mlammary
adleniocarciiioimia
Comments
Biopsy 1: XWell differentiated.
2: Major areas of necrosis.
3: Tumour tissue surroundle(l by muscle.
4: Areas of haemorrhage.
l3iopsy 1: 'P'oorly differentiated fusiform cells with frequient mitotic
figures. Generally avascular.
2: Small areas of well differentiated cells with occasional
mitotic figures. Some vascular structures.
3: Well differentiated rounded cells arranged in "whorls"
around amorphous deposits. Alitotic figures rare. Good
vascular supply.
'I'iimary ani(d metastatic t,umour composedt of invadling poorlly
differentiated ttubuflar carcinomatous tissuc.
4 C'utaneous Mixed lymphoblastic and lymphocytic type.
lymphosarcoma
5 Fibrosarcoma Well lifferentiated.
6 Squamouis cell carcinoma Poorly (lifferentiated and invasive. Large areas of haemorrhage.
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poiidinig plasma concentrations. For Cases
3 and 4 the concentrations are also plotted
against time (Figs 3 and 4).
For Cases 1 and 2 the plasma nitroimid-
azole concentrations were measured at a
single time only, just, before euthanasia.
Peak MIS concentrations were recorded
at I h for Cases 4 and 5 and at 2 h for
Cases 3 and 6, the plasma concentrations
thereafter falling gradually in all cases.
Peak plasma metabolite concentrations
were more variable, peak values being
TA13LE IN. Concentration ofMIS and Ro 05-9963 in biopsies after 150 mng/lkg MIS i.v.
a: Case 1 Osteosarcoma, 1P5 l1 after injection
Sample
IPlasina
"Hiealthy" tumour
Necrotic tuLmotur
Tumour-muscular attachment
Haernorrhagic tutmour
Overall meaan
1ils Ro 05-9
(Hg/ml) (fig/rr
218 7-5
16.5
17:3
126 -
140
151 22 (s.d.) < 10
b: Case 2 Meningioma 3-5 h after injection
Samnple
Plasma
C(SF
Normal brain
Cerebrum
Thalamtis
('erebelluoin
Braini stem
Mlean
Tumour biopsy I
3 Mean~~~~~~:
'I' S
( gz/inl)
243
273
117
107
106
125
114 + 9
42
83
1 (0)
78 +34
c: Ca,se 3-Mamnmnary adenocarcinoma biopsies u
TimneI lI S
(b1) (Lg/iml)
1 284
2 261
3 213
4 227
5 216
IPlasma
Ro 05 996:3
()Ug/rl)
9-2
10.9t
10 .9
1
09
12-5
13-8
MIS
( Ha-lg)
19(
185
185
160
120
Ho 05-9963
(1tg/ml)
7-4
2-9
< 10
< 10
0,) Tumour:
)96:3 )lasina
nl) ratio (MIIS)
76
79
58
64
69 + 10 (8.d.)
0) Sample:
plasma
i-atio (AIIS)
112
48
41
44
51
473+3
17
.,4
45
32+ 14
p to 5 h after injection
Tumouir Tumour:
plasma
Ro 05-9963 ratio
(Itzg7g) pl1IS)
7-8 67
14-1 69
10-5 95,t
I1.( 68
11-5 56
cl: Case 4 C(utatieouLs lymphosarcomna biopsies up to 5 Ii after injectioln
Plasma Tuimotur
Tit-e
(h)
1
2
3
4
5
Mls
( rg/ml)
188
191
154
137
124
Ro 05-996:3
( ig7ml)
6-.3
7-6
6-3
5.9
7-3
Cr--
(Oxg/g)
131
125
101
74
15
°0 Tumoumr:
plasma i-atio
7()
65
66
54
76
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TABLE IV (cont.)
e: Fibrosarcoma biopsies up to 5 h after injection
Plasma
Time MIS
(h) (tLgIml)
1 250
2 224
3 218
4 196
5 189
Ro 05-9963
(Zg/ml)
5.3
6-3
5-1
4-7
7 0
MIS
(Lg/ml,
159
146
157
146
116
Tumour
% Tumour:
plasma ratio
63
65
72
74
61
f: Squamous cell carcinoma biopsies up to 5 h after injection
Plasma
Time MIS Ro 05-99(
(h) (Kg/ml) (pg/ml)
1 261 4-9
2 262 5-2
3 223 4-1
4 223 5-3
5 214 5-0
recorded at 2 h for Cases 4 and 5, 4 h for
Case 6 and 5 h for Case 3.
(iii) Tnumour MIS and metabolite concen-
trations. Case I (osteosarcoma). The MIS
concentrations for the 4 simultaneous
tumour biopsy specimens are recorded in
Table IVa. There was little variation in
the concenitrations between the samples,
the lowest (126 /tg/ml) being recorded in
the tumour at its muscular attachments,
whilst the highest (173 aug/ml) was found
in the necrotic region of the tumour.
The overall mean value for the tumour:
plasma concentration ratio was 69 + 10%.
Case 2 (meningioma). The CSF MIS
concentration (243 jug/ml) at the time of
euthanasia represents 112%0 of the plasma
concentration (Table IVb). MIS concen-
trations in normal brain were lower than
in the CSF, but were fairly similar in the
various areas ofnormal brain, representing
an overall mean of 47 + 3%0 of the plasma
concentration.
Variation in MIS concentration was,
however, seen in the various biopsy speci-
mens taken simultaneously from the
tumour. The concentrations of MIS in the
poorly differentiated and avascular tumour
areas of Biopsy Specimens 1 and 2 (see
Table IVb) were 42 and 83 ,ug/ml, repre-
senting 17 and 34%0 of the plasma con-
centration. A concentration similar to that
Tumour
MIS % Tumours:
(Pg/g) plasma ratio
198 76
149 57
148 66
105 47
151 71
E
-W
cm 350-
h. 300
0
E 250- U)
53 150-
0.
2400-
IV
*E 50
z A------- A AL
I I I
1 2 3 4 5
Time (h)
6
FiG. 3. Plasma an(d tumour nitroimidazole
concentrations in a bitch bearing multiple
metastases from a mammary adenocar-
cinoma, after 150 mg/kg i.v. MIS.
0 Plasma MIS; 0 Tumour MIS; A
Plasma Ro 05-9963; A Tumour Ro 05-9963.
for normal brain, of 109 jug/ml (45% of
plasma concentration), was found in
Biopsy Specimen 3, which was composed
of well differentiated tumour cels and was
well vascularized.
Case 3 (mammary adenocarcinoma). The
tumourMIS concentration was maintained
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at a fairly constant level during the first
3 h and thereafter declined gradually
(Fig. 3). The overall mean tumour:plasma
concentration ratio was 71 + 14%.
Case 4 (cutaneous lymphosarcoma). The
maximum tumour concentration wNas
achieved at 1 h and thereafter the con-
centration steadily declined up to 5 h. The
overall mean tumour: plasma concentra-
tion ratio was 66 + 8%.
E
E
a
z
250-
200-
150-
100-
50-
A A A A
1 2 3 4 5 6
Time (h)
Fia. 4. Plasma and tumour nitroimidazole
concentrations in a bitch bearing multiple
cutaneous lymphosarcomas after 150 mg/kg
iv. MITS. * Plasma MIS; 0 Ttumotur iMIS;
Plasma Ro 05-9963.
Case 5 (fibrosarcoma). The tumour MIS
concentration was maintained at a steadv
level for the first 4 h in this case. The
overall mean tumour: plasma ratio was
67 + 6°,.
Case 6 (squamous cell carcinoma). The
pattern of MIS concentration in this
tumour was somewhat variable, after being
maintained at fairly constant level during
the first 3 h (Table IVe). The overall
mean tumour: plasma concentration ratio
was 63 + 120.
The concentrations of Ro 05-9963 in the
tumour samples were measurable only in
the mammary adenocarcinoma, and are
recorded in Table lVc. For all other
tumour samples the preparation tech-
nique (I vol tunmour: 9 vol distilled water)
reduced the concentration of the metabo-
lite below 1 Mug/ml, and coneentrations are
therefore recorded as <10 lOg/ml.
In Case 3 the tumour metabolite con-
centration rose to a maximum at 2 h andI
was maintained at a fairly steady level up
to 5. The overall mean tumour:plasma
concenitration ratio -was high (97 + 19O/),
values at 2 and 3 h showing more than
complete penetration by the metabolite.
DISCUSSlON
WVe have studied the concentrations of
MIS and its metabolite, Ro 05-9963, in 6
spontaneous canine tumours after doses
of 150 mg/kg i.v. in order to investigate the
relationship between tumour and plasma
concentrations and to elucidate the opti-
mum timing for the irradiation of tumours
after the administration of MIS.
Because of the necessity for general
anaesthesia in the 4 dogs from which serial
biopsy specimens were removed, we have
also studied the effect of the simnultaneouis
administration of sodiuim pentobarbitone
on the pharmacokinetics of MIS in 2 dogs.
These findings may be compared w%rith the
data previously reported by White et al.
(1 979) for the pharmacokineties of MIS in
unanaesthetized dogs.
After sodium pentobarbitone anaes-
thesia, the pattern of MIS elimination
from the plasma was not markedly
altered. Peak plasma concentrations
occurred at about the same time, anid the
half-life of MIS remained witlhin the pre-
viously reported range (4.9-6 7 h as com-
pared with a range of 3 2-6 9 h). Some
differences were noted, however, firstli,
the peak plasnma MIS concentrationis wrere
raised after anaesthesia bv 11-13% to
values of 200 an(I 223 jtg/ml. How%rever,
these values were within the racnge pre-
viously found (172-224 tig/ml) at the dose
of 150 mg/kg i.v. (WNhite et al., 1979).
Secondly, as a result of the raised peak
plasma values the total AU(C after anaes-
thesia was raised by 23 acnd 34% respec-
tively, to 1942 and 2489 tg/ml.h. These
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values were rather higher than the pre-
viously reported range for this dose (1357-
1740 ug/ml.h). Thirdly, the metabolismn of
MIS to the 0-demethylated metabolite,
Ro 05-9963, appeared to be delayed by
barbiturate anaesthesia, reducing and
delaying peak plasma concentrations. The
total availability of the metabolite, how-
ever, remained unaltered.
The delayed metabolism of MIS, which
may well be due to competition with the
barbiturate for conmmon metabolizing
enzymes, probably accounts for the early
high MIS concentrations observed in the
2 anaesthetized dogs.
The above findings suggest that peak
plasma MIS concentrations would be
somewhat higher in the dogs anaesthetized
for the purpose of biopsy. This was in fact
the case, and all anaesthetized dogs
showed peak plasma concentrations at the
upper limit of, or greater than, the normal
range for this dose (184-225 Htg/ml).
Tumour penetration was good in all
cases in this study except Case 2 (meningi-
oma), with values ranging between 47 and
95%0 of the plasma concentration. In
Cases 3-6 the maximum tumour concen-
tration was achieved at 1 h, high concen-
trations being maintained during the first
3 h after drug administration.
MIS appears suitable as a radiosensi-
tizing agent for veterinary radiotherapy,
rapid and high concentrations being
achieved in tumours after i.v. dosage, and
the timing of radiotherapy not critical
within the first 3 h after dosage. The
range of maximum tumour concentrations
achieved in this study again excepting
Case 2 (131-198 ,ug/ml) indicate that
enhancement ratios in the range of 1.8-2 0
might be expected for the response of
tumours at this dose level (Dische et al.,
1,977).
We have also investigated the concen-
trations of MIS and Ro 05-9963 achieved
in the cerebrospinal fluid of the anaes-
thetized dogs, since the penetration of
CSF may well be an important considera-
tion in predicting the neurotoxicity of the
drug and also for the timing of radio-
therapy for brain tumours in man. Little
data are available for the penetration of
CSF by MIS. However, Urtasun et al.
(1977) recorded a level of 82% in a sample
taken by lumbar puncture 5-5 h after a
dose of 4 g in a patient with a brain
tumour. Lu et al. (1978) state simply that
the plasma and CSF concentrations are
identical during the drug's elimination
phase in the dog.
The CSF concentrations recorded in this
study indicated good penetration by the
drug, almost complete penetration occur-
ring at 3 h in both dogs. This was notably
later than the time of peak penetration in
the tumour in Cases 2-6. MIS appeared
able to pass into the CSF freely during the
period studied, and ranges of 81-97% and
46-950% were recorded. The metabolite,
Ro 05-9963, appeared to pass into the
CSF less well, and concentrations ranged
between only 15-58% and 0-43% of the
plasma concentrations respectively.
Despite the high degree of penetration
recorded in the CSF (1120o) of Case 2
(meningioma) it appears the dog's braini is
only moderately well penetrated by MIS
at 3 5 h. The mean concentration found in
the brain samples was 114 + 9 jug/ml
(47 + 3% of the plasma concentration).
Although there was little variation be-
tween the concentrations found in the
normal brain, considerable differences
were noted between the tumour samples.
In the well differentiated and vascular
area of Biopsy Specimen 3 the concentra-
tion was similar to that elsewhere in
normal brain (450o), whilst in the poorly
differentiated and relatively avascular
areas of Biopsy Specimens 1 and 2 the
concentrations represented only 17 and
340% of the plasma concentration. It is
debatable whether these variations were
attributable to the histological and vascu-
lar patterns.
The estimation of the concentration of
MIS in tumours will be a valuable guide to
the correct timing of radiotherapy to
achieve the maximum enhancement of the
tumour response, and also in evaluating
the likely degree of enhancement. It is
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important to establish what relationship,
if any, exists between tumour anid plasma
MIS concentrations.
The mouse has been regarded as a poor
species in which to investigate such a
relationship, since it has generally been
held that the short half-life of MIS in the
mouse has led to poor tumour concentra-
tions and a lower tumour: plasma ratio
than in man. Dische et al. (1977) reported
concentrations of less than 40%0 of the
plasma concentration in mouse tumours,
and similar levels have been recorded else-
where (McNally et al., 1978).
Cenerally higher levels were reported in
man by ("ray et al. (1976) but considerable
variation was recorded between tumours
(12-92%o). Subsequent reports showed less
variation, but the same high degree of
penetration: 37-107% (Dische et al., 1977),
50-70% (Wiltshire et al., 1978) and
50-100%0 (Workman et al., 1978b).
XVith the exception of Case 2 (meningi-
oma) the range of penetration values in
this stu(y (47-95°0) closely resembles the
range previously reported in man. The
mean values for the tumour: plasma ratios
for these cases were remarkably constant
(69, 71, 66, 67 and 63%) with only small
degrees of variation, suggesting that
tumour concentrations were largely a
function of the available plasma concen-
trations.
The assumption that the higher tumour
penetration values seen in man have been
the result of the relatively long half-life of
MIS in man has recently been challenged
by Brown et al. (1979), who recorded
tumour: plasma ratios ranging from 50
to 70%0 in the mouse, and demonstrated
that this level of penetration remained
unaltered when the half-life of MIS was
artificially prolonged from 1P5 to 10 h by
bilateral renal ligation of the mice. These
workers concluded that the tumour pene-
tration in mice was in fact similar to that
in man and that any variation was likely
to be the result of individual tumour type.
With the exception of the brain tumour
in this study, the range oftumour penetra-
tion values indicated a similar tumour:
plasma concentration relationship to both
mouse and man. WAe conLcur with the con-
clusion of Brown et al. (1979) that the
tumour concentration is dependant more
upon the available plasma concentration
than on the half-life ofMIS in the particu-
lar species.
Although the mouse may well be a better
species for the study of tumour penetra-
tion by MIS than at first thought, it nmay
prove a poor model for the investigation of
other radiosensitizing drugs which are
more hydrophilic than MIS and have
shorter half-lives. The intermediate half-
life of MIS in the dog indicates that this
species will provide a better opportunity
for pharmacokinetic studies of such drugs
in a physiologically normal model. Fur-
thermore, the incidence of spontaneous
tumours in the dog, of varying histological
types, some of which closely resenmble the
situation in man, will allow the investiga-
tion of tumour penetration by such radio-
sensitizing drugs and provide a valuable
guide to the concentrations likely to be
achiieved in tumours in man.
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